PracticeUpdate: Dermatology - Winter 2018

See the evidence for continuous CONTROL *69%of patients achieved EASI-75 at 16 weeks and 65% achieved EASI-75 at 52 weeks. 1

* 1,3

Rapid # and sustained † improvement in: • Lesion extent and severity 1–4 • Pruritus intensity 1–4 • Quality-of-life measures 1,2 # Rapid – at 2 weeks. 1,2 † Sustained – out to 52 weeks. 1,2

52 week safety and tolerability profile with no monitoring for organ toxicities required 4 • The most common adverse reactions were injection site reactions, conjunctivitis, blepharitis, and oral herpes. 4

The FIRST BIOLOGIC for adults with moderate-to-severe ATOPIC DERMATITIS 4 NOW TGA APPROVED 4 INDICATION DUPIXENT is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. Dupixent is not intended for episodic use. Please review full Product Information before prescribing. Full Product Information is available from Sanofi-Aventis Australia Pty Ltd at http://www.sanofi.com.au or 1800 818 806 Dupixent (Dupilumab) MINIMUM PRODUCT INFORMATION. INDICATIONS: Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for chronic systemic therapy. Not intended for episodic use. DOSAGE ANDADMINISTRATION: Initial dose of 600 mg by subcutaneous injection (two 300 mg injections consecutively in different injection sites), followed by 300 mg given every other week. Refer to full PI for preparation, handling and administration. CONTRAINDICATIONS: Hypersensitivity to dupilumab or any of its excipients. PRECAUTIONS: Record the tradename and the batch number to improve traceability. Hypersensitivity, helminth infections, conjunctivitis and keratitis, comorbid asthma, concomitant atopic conditions. INTERACTIONS: Live vaccines, No safety data on co-administration with other immunomodulators. Refer to full PI. ADVERSE EFFECTS: Injection site reactions, conjunctivitis, conjunctivitis allergic, oral herpes, conjunctivitis bacterial, herpes simplex, eosinophilia, eye pruritus, blepharitis, dry eye, hypersensitivity. NAME OF SPONSOR: Sanofi-Aventis Australia Pty Ltd, 12-24 Talavera Road, Macquarie Park, NSW 2113. Based on Full Product Information with TGA date of approval of 15 March 2018. References: 1. Blauvelt A et al. Lancet. 2017; 389(10086):2287–2303. 2. Blauvelt A et al. Lancet. 2017; 389(10086). Supplementary Appendix. 3. Simpson EL. Dermatol Ther (Heidelb) 2017; 7(2):243–248. 4. Australian Approved Product Information for Dupixent. PBS INFORMATION: This product is not listed on the PBS.

Sanofi and Regeneron are collaborating in a global development program and commercialization for DUPIXENT.

© 2018 Sanofi-Aventis Australia Pty Ltd trading as Sanofi Genzyme – ALL RIGHTS RESERVED. Sanofi-Aventis Australia Pty Ltd trading as Sanofi Genzyme ABN 31 008 558 807. Talavera Corporate Centre. Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. www.sanofigenzyme.com.au. Date of preparation May 2018. GZANZ.DUP.18.02.0021 SAG0151